Loading page…

Oxygenta Pharmaceutical Ltd (OXYGENTAPH) · mywealthgrid

About

Small-cap pharmaceutical company with market cap ₹249.49 Cr. Revenue accelerated 7× from ₹6.86 Cr (Jun 2023) to ₹49.47 Cr (Mar 2025). Unprofitable in 7 of last 8 quarters (operating margin -8.7%) except Mar 2024, which reported ₹8.02 Cr profit.

Face value: ₹10

Market cap

₹178 Cr

P/E

—

P/B

—

Dividend yield

ROE

—

ROCE

-51.8%

Debt / equity

—

OPM

-13.6%

EPS (TTM)

₹-2.8

Book value

₹-11.5

52-week high

₹70.0

52-week low

₹44.6

Key insights

Company research notes and source-linked reviews

Key risks

Chronic losses in 7 of last 8 quarters; only Mar 2024 profitable (₹8.02 Cr). Verify what enabled profitability and whether repeatable.
Negative margins not scaling: OPM ranged from -2.45% (Mar 2025) to -53.03% (Jun 2023). Verify cost structure and path to breakeven.
Investor exit: stock down 31.19% in 1 year and halved from ₹98.2 high; FII 0%, DII 0.03%. Verify if losses are priced in or reflect deeper concerns.
Execution risk after years of losses: must grow revenue and cut costs concurrently. Verify management plan and track record.

Generated analysis · source review pending

Growth drivers

Revenue base 7× in 9 months (₹6.86 Cr Jun 2023 → ₹49.47 Cr Mar 2025); verify drivers: new products, markets, or project revenue.
Operating margin trend from -53.03% (Jun 2023) to -2.45% (Mar 2025); verify if cost structure now scales with revenue.
Mar 2024 showed profitability (₹8.02 Cr profit) at ₹10.55 Cr revenue; verify conditions and repeatability at current scale.
Operating leverage potential if revenue growth continues and fixed costs stabilize; verify fixed vs variable cost breakdown.

Generated analysis · source review pending

₹48.0-31.4%1Y

Beta

0.57

Damps index moves

Volatility (1y)

57.2%

Annualised, daily returns

RSI (14)

27.3

Oversold territory

Rel. strength (1y)

-41.1%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Revenue CAGR of 16.8% over the last 5 years

Cons

−Weak interest coverage of -3.6×

Research score

Structured signal from quality, growth, valuation and momentum.

45/100

Business quality: 0
Growth: 67
Valuation: 100
Momentum: 14

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	12	7	13	21	14	52	61	31	40	109	113
COGS	-8	-5	-6	-16	-16	37	47	24	34	96	102
Gross profit	—	—	—	—	—	15	13	7	6	13	11
	25	18	23	39	37	12	12	14	16	23	26
	-4	-6	-4	-2	-8	4	1	-7	-10	-10	-15
OPM %	-33.5%	-77.3%	-31.2%	-10%	-57.3%	7.4%	2.4%	-22.9%	-24.5%	-9.2%	-13.6%
Depreciation	1	1	1	1	1	1	2	2	3	2	2
Interest	—	1	1	1	1	2	1	1	2	4	5
	—	—	—	—	—	2	1	-1	0	1	0
Profit before tax	-6	-6	-4	-3	-6	3	-0	-11	-14	-14	-22
Tax	—	—	—	—	—	0	0	0	-10	-4	-5
Tax %	—	—	—	—	—	6.7%	24.5%	1.8%	-74.9%	-28.2%	-20.8%
	-6	-6	-5	-3	-6	3	-1	-12	-3	-10	-18
PAT margin %	-46.3%	-79.4%	-35.2%	-15.9%	-42.2%	5.6%	-1%	-37.3%	-8.8%	-9.4%	-15.6%
EPS (₹)	—	-5.7	-4.2	-3.2	-5.7	2.9	-0.1	-8.2	-1.1	-2.9	-4.8
EPS adjusted (₹)	—	—	—	—	-5.7	2.9	-0.4	-8.2	-1	-2.8	-4.8
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	10	10	14	14	33	37	37
Reserves	-51	-48	-49	-60	-54	-63	-80
Minority interest	—	—	—	—	0	—	—
	26	48	52	68	57	62	110
	34	24	14	32	26	46	53
Total equity & liabilities	19	34	31	54	63	83	120
	11	16	20	28	29	37	48
CWIP	0	1	0	—	—	0	0
Investments	0	0	0	0	0	0	0
	7	17	11	26	34	46	72
Total assets	19	34	31	54	63	83	120

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-2	-2	-2	-13	3	-28
	-7	-5	-10	-4	-11	-14
	9	6	11	17	9	43
Net cash flow	0	-0	-0	-0	0	0
Free cash flow	-8	-7	-11	-17	-9	-41
CFO / Operating profit %	-42.1%	-115.1%	—	—	—	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	29.6%	22%	22.5%	15.4%	11.7%	9.6%
EBITDA margin %	-10%	-57.3%	7.4%	2.4%	-22.9%	-24.5%	-9.2%	-13.6%
EBIT margin %	-14.9%	-64.6%	5.1%	-0.2%	-29.6%	-31.2%	-10.8%	-15.7%
PAT margin %	-15.9%	-42.2%	5.6%	-1%	-37.3%	-8.8%	-9.4%	-15.6%
Working capital
Receivable days	—	11	11	10	120	68	17	32
Inventory days	—	72	121	56	178	149	78	105
Payable days	—	137	137	50	362	249	113	174
NWC days	—	-54	-5	16	-64	-32	-18	-37
Leverage
Current ratio	—	0.43	0.91	1.19	0.76	0.72	0.36	0.6
Debt to EBITDA	—	—	12.44	35.71	—	—	—	—
Debt to equity	—	-0.63	-1.26	-1.51	-1.47	-2.84	-2.43	-2.57
Interest coverage	-4.1	-8.1	1.5	-0.1	-6.1	-7.7	-2.9	-3.6
Asset turnover	—	0.74	1.54	1.94	0.57	0.63	1.32	0.94
Return ratios
Return on assets %	—	-31.1%	8.7%	-2%	-21.3%	-5.5%	-12.4%	-14.7%
Return on capital employed %	—	-319.9%	28.6%	-0.6%	-41.1%	-48.5%	-79.2%	-51.8%
Return on equity %	—	14.1%	-7.7%	1.8%	25%	17.3%	40.2%	41.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	29.73%	29.73%	29.73%	33.69%	53.28%	51.12%	51.12%	57.92%	57.95%	55.93%	56.54%	56.54%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	70.24%	70.24%	70.24%	66.28%	46.69%	48.85%	48.85%	42.05%	42.02%	44.04%	43.43%	43.43%
No. of shareholders	—	—	—	—	—	—	—	—	10,179	10,215	10,205	10,196

Promoter holding up 26.81 percentage points since Sep 2023.

4 deals · 15 Dec 2025 – 13 Feb 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
13 Feb 2026	DEVARAPALLY VENKATESWARA REDDY	Bulk	BSE	Sell	3,00,000	₹46.99	₹1.41 Cr
13 Feb 2026	VIRUPAKSHA ORGANICS LIMITED	Bulk	BSE	Buy	2,23,632	₹46.60	₹1.04 Cr
15 Dec 2025	DEVARAPALLY VENKATESWARA REDDY	Bulk	BSE	Sell	2,04,472	₹54.30	₹1.11 Cr
15 Dec 2025	VIRUPAKSHA ORGANICS LIMITED	Bulk	BSE	Buy	1,95,885	₹54.25	₹1.06 Cr

1–4 of 4

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Chandra Mouliswar Reddy GangavaramExecutive Director
Mr. Balasubba Reddy MamillaExecutive Director
Mrs. Vedavathi GangavaramNon-Executive - Non Independent Director
Mr. Sidda Reddy KanuparthiNon-Executive - Independent Director
Mr. Veera Reddy AravaNon-Executive - Independent Director
Mrs. Sharvari Swapnil ShindeNon-Executive - Independent Director
Mr. Amireddy Venkatesu ReddyExecutive Director
Mr. Janardhana Reddy YeddulaNon-Executive - Independent Director
Mr. Prasad Reddy BattinapatlaChief Financial Officer
Ms. Kumkum BajajCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Oxygenta Pharmaceutical Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

2

Board meeting to consider results27 Jul 2026
Board meeting to consider results25 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

14 announcementsExport CSV

1 Oct 2026, 5:58 pmCompany Update

Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015-Purchase Of Land

General PDF

29 Sept 2026, 11:03 amInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

21 Aug 2026, 4:51 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

21 Aug 2026, 4:47 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

31 Jul 2026, 12:09 pmCompany Update

Newspaper Advertisement

General PDF

30 Jul 2026, 5:12 pmAGM/EGM

Intimation Of Book Closure And Cut-Off Date For The 33Rd Annual General Meeting Of Oxygenta Pharmaceutical Limited.

AGM PDF

30 Jul 2026, 5:06 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

30 Jul 2026, 5:00 pmAGM/EGM

Submission Of Notice Of 33Rd Annual General Meeting For The Finanical Year 2025-26.

AGM PDF

Date	Category	Subject	Filing
1 Oct 2026, 5:58 pm	Company Update General	Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015-Purchase Of Land	PDF
29 Sept 2026, 11:03 am	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window

Loading announcements…

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

2

Announcements

2

Not in the F&O segment

Announcements

Annual reports

No fund holdings on record

Compounded sales growth

Stock price CAGR

Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings2

Announcements

Board meetings2

Not in the F&O segment

Announcements

Annual reports

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

No fund holdings on record

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Stock price CAGR

2

2